Related Experiment Video
Updated: May 23, 2026
Ex Vivo Culture of Circulating Tumor Cells in the Cerebral Spinal Fluid from Melanoma Patients to Study Melanoma-Associated Leptomeningeal Disease
Published on: March 29, 2024
Comparison of growth factor signalling pathway utilisation in cultured normal melanocytes and melanoma cell lines
Ji Eun Kim1, Clare Stones, Wayne R Joseph
1Auckland Cancer Society Research Centre, The University of Auckland, Auckland, New Zealand. jieun.kim@auckland.ac.nz
Background:
The phosphatidylinositol-3-kinase (PI3K-PKB), mitogen activated protein kinase (MEK-ERK) and the mammalian target of rapamycin (mTOR- p70S6K), are thought to regulate many aspects of tumour cell proliferation and survival. We have examined the utilisation of these three signalling pathways in a number of cell lines derived from patients with metastatic malignant melanoma of known PIK3CA, PTEN, NRAS and BRAF mutational status.
Methods:
Western blotting was used to compare the phosphorylation status of components of the PI3K-PKB, MEK-ERK and mTOR-p70S6K signalling pathways, as indices of pathway utilisation.
Results:
Normal melanocytes could not be distinguished from melanoma cells on the basis of pathway utilisation when grown in the presence of serum, but could be distinguished upon serum starvation, where signalling protein phosphorylation was generally abrogated. Surprisingly, the differential utilisation of individual pathways was not consistently associated with the presence of an oncogenic or tumour suppressor mutation of genes in these pathways.
Conclusion:
Utilisation of the PI3K-PKB, MEK-ERK and mTOR-p70S6K signalling pathways in melanoma, as determined by phosphorylation of signalling components, varies widely across a series of cell lines, and does not directly reflect mutation of genes coding these components. The main difference between cultured normal melanocytes and melanoma cells is not the pathway utilisation itself, but rather in the serum dependence of pathway utilisation.
Insights
Melanoma cell signaling pathways like PI3K-PKB, MEK-ERK, and mTOR-p70S6K show varied utilization not directly tied to gene mutations. The key difference lies in their serum dependence, not pathway activity itself.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Signaling
Background:
- Investigates key signaling pathways (PI3K-PKB, MEK-ERK, mTOR-p70S6K) crucial for tumor cell proliferation and survival.
- Examines these pathways in metastatic malignant melanoma cell lines with known genetic mutation status (PIK3CA, PTEN, NRAS, BRAF).
Purpose of the Study:
- To determine the utilization of PI3K-PKB, MEK-ERK, and mTOR-p70S6K signaling pathways in melanoma.
- To correlate pathway utilization with specific gene mutations in melanoma cell lines.
Main Methods:
- Western blotting was employed to assess the phosphorylation status of signaling pathway components.
- Pathway utilization was inferred from the phosphorylation levels of key proteins.
Main Results:
- No significant difference in pathway utilization was observed between normal melanocytes and melanoma cells in serum-rich conditions.
- Serum starvation abrogated signaling protein phosphorylation, revealing differences between cell types.
- Pathway utilization did not consistently correlate with the presence of oncogenic or tumor suppressor mutations.
Conclusions:
- Signaling pathway utilization in melanoma is diverse and not directly dictated by mutations in the genes encoding these components.
- The primary distinction between melanoma cells and normal melanocytes is their differential dependence on serum for pathway activation.
Related Concept Videos
02:38Mitogens and the Cell Cycle
03:03mTOR Signaling and Cancer Progression
The mTOR pathway or the...
01:19Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...